Atossa Genetics (NASDAQ:ATOS) Price Target Raised to $25.00 at HC Wainwright

Atossa Genetics (NASDAQ:ATOS) had its target price hoisted by HC Wainwright to $25.00 in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities analysts have also weighed in on ATOS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. Ascendiant Capital Markets upped their price objective on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $68.33.

Atossa Genetics Stock Down 13.1%

ATOS opened at $4.71 on Thursday. The business has a 50 day moving average price of $5.80 and a two-hundred day moving average price of $9.98. The company has a market cap of $40.55 million, a PE ratio of -1.31 and a beta of 1.42. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35.

Hedge Funds Weigh In On Atossa Genetics

Large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Atossa Genetics by 4.2% in the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after buying an additional 245,717 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in Atossa Genetics during the second quarter worth $2,468,000. Renaissance Technologies LLC raised its position in Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares in the last quarter. Graham Capital Management L.P. raised its position in Atossa Genetics by 27.8% in the fourth quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock worth $125,000 after acquiring an additional 45,923 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in Atossa Genetics by 51.3% in the fourth quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock valued at $105,000 after acquiring an additional 37,809 shares during the period. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.